SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ABTI Alpha-Beta Technology
ABTI 0.200+99,900.0%Jun 17 12:34 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (341)7/30/1997 3:19:00 PM
From: Cacaito   of 572
 
ncbi.nlm.nih.gov Notice is from same month, same year as previously post, but different article.

This is the article you refer to and the significant p=0.5 (3.4 infections per infected patient vs. 1.4 infections per infected patients) Only 34 patients, and what do they mean per infected patient? what did it happen to the none infected patients? all were infected?

The value apparently was in the decrease of intravenous antibotics days (10.3days vs 0.4 days).

Shorter intensive care unit length of stay (3.3 days vs 0.1 days). But nothing about the total hospital stay. Anyway with many surgical procedures done as outpatient, and many intensive care unit days cut by the HMOs (HMOs are relativily recent in New England). How is this going to show when the average days in ICUs have being already cut by HMOs? it will be more difficult to prove an effect.

The only conclusion from both articles is: Betafectim does not kill patients, does not get them sicker, is safe (so far) and efficacy is to be proved (nice hope,not a nice fact).

What about mortality? if one is going to charge for an expensive ICU drug, it is not to show decrease infections, or decrease hospital stay. One must show decrease mortality or face a difficult FDA road.

The 2nd week of August will tell.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News